Contribution of QnrA, a plasmid-mediated quinolone resistance peptide, to survival of Escherichia coli exposed to a lethal ciprofloxacin concentration

Japanese Journal of Infectious Diseases

Volumn 68, Issue 3, 2015, Pages 196-202

  Goto, Kensuke ^a   Kawamura, Kumiko ^a   Arakawa, Yoshichika ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASSOCIATION; COMPUTER MODEL; CONTINGENT VALUATION; DECISION MAKING; EXPECTATION; FEMALE; FOLLOW UP; GRAMMAR; HEARING; HUMAN; INFORMATION; MALE; MISMATCH NEGATIVITY; PHONETICS; PREDICTION; QUALITATIVE ANALYSIS; SCORING SYSTEM; SPEECH ARTICULATION; SPEECH DISCRIMINATION; SPEECH PERCEPTION; TASK PERFORMANCE; WORD RECOGNITION; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY;

ANTIINFECTIVE AGENT; CIPROFLOXACIN; ESCHERICHIA COLI PROTEIN; QNR PROTEIN, E COLI;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 84929395704     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.JJID.2014.153     Document Type: Article

References (29)

1. Neuhauer MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-8.
2. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43: 2736-41.
3. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;61:273-81.
4. Hooper DC. Mechanism of fluoroquinolone resistance. Drug Resist Updat. 1999;2:38-55.
5. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A. 2002;99:5638-42.
6. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolonemodifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12:83-8.
7. Yamane K, Wachino J, Suzuki S, et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2007;51:3354-60.
8. Hansen LH, Johannesen E, Burmølle M, et al. Plasmid-encoded multidrug efflux pump conferring resistance to olaquindox in Escherichia coli. Antimicrob Agents Chemother. 2004;48:3332-7.
9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. Document M100-S23. Wayne, PA: CLSI; 2013.
10. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1. 2013. Available at ‚
11. Strahilevitz J, Jacoby GA, Hooper DC, et al. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev. 2009;22:664-89.
12. Fonseca EL, Vicente AC. Epidemiology of qnrVC alleles and emergence out of the Vibrionaceae family. J Med Microbiol. 2013;62:1628-30.
13. Allou N, Cambau E, Massias L, et al. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother. 2009;53:4292-7.
14. Lau SH, Reddy S, Cheesbrough J, et al. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. J Clin Microbiol. 2008;46: 1076-80.
15. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991;4:80-128.
16. Rice JC, Peng T, Kuo YF, et al. Renal allograft injury is associated with urinary tract infection caused by Escherichia coli bearing adherence factors. Am J Transplant. 2006;6:2375-83.
17. Clermont O, Lavollay M, Vimont S, et al. The CTX-M-15- producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother. 2008;61:1024-8.
18. Clinical and Laboratory Standards Institute (CLSI). Methods for determining bactericidal activity of antimicrobial agents, approved guideline. Document M26-A. Wayne, PA: CLSI; 1999.
19. Marcusson LL, Olofsson SK, Komp Lindgren P, et al. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother. 2005; 55:938-43.
20. Rodriguesz-Martinez JM, Velasco C, Pascual A, et al. Correlation of quinolone resistance levels and differences in basal and quinolone-induced expression from three qnrA-containing plasmids. Clin Microbiol Infect. 2006;12:440-5.
21. Briales A, Rodriguesz-Martinez JM, Velasco C, et al. In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against Escherichia coli isolates with mutations in gyrA and parC. Antimicrob Agents Chemother. 2011;55:1266-9.
22. Rodriguesz-Martinez JM, Velasco C, Garcia I, et al. Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA 1. Antimicrob Agents Chemother. 2007;51: 2236-9.
23. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 1996;40:879-85.
24. Yu X, Susa M, Knabbe C, et al. Development and validation of a diagnostic DNA microarray to detect quinolone-resistant Escherichia coli among clinical isolates. J Clin Microbiol. 2004;42: 4083-91.
25. Cesaro A, Bettoni RR, Lascols C, et al. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes. J Antimicrob Chemother. 2008;61: 1007-15.
26. Chong YP, Choi SH, Kim ES, et al. Bloodstream infections caused by qnr-positive Enterobacteriaceae: clinical and microbiologic characteristics and outcomes. Diagn Microbiol Infect Dis. 2010;67:70-7.
27. Allou N, Cambau E, Massias L, et al. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother. 2009;53:4292-7.
28. Jakobsen L, Cattoir V, Jensen KS, et al. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. J Antimicrob Chemother. 2012;67:2438-44.
29. Domínguez-Herrera J, Velasco C, Docobo-Peárez F, et al. Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu. J Antimicrob Chemother. 2013;68:1609-15.